Sidoti Estimates Cibus’ Q1 Earnings (NASDAQ:CBUS)

Cibus, Inc. (NASDAQ:CBUS) – Stock analysts at Sidoti cut their Q1 2026 earnings per share estimates for Cibus in a research report issued to clients and investors on Wednesday, May 13th. Sidoti analyst A. Hantman now anticipates that the company will earn ($0.36) per share for the quarter, down from their previous estimate of ($0.32). The consensus estimate for Cibus’ current full-year earnings is ($1.13) per share. Sidoti also issued estimates for Cibus’ Q2 2026 earnings at ($0.36) EPS, Q3 2026 earnings at ($0.36) EPS, Q4 2026 earnings at ($0.36) EPS, FY2026 earnings at ($1.45) EPS, Q1 2027 earnings at ($0.28) EPS, Q2 2027 earnings at ($0.29) EPS, Q3 2027 earnings at ($0.28) EPS, Q4 2027 earnings at ($0.29) EPS and FY2027 earnings at ($1.14) EPS.

CBUS has been the subject of a number of other research reports. Jefferies Financial Group upped their price objective on Cibus from $1.90 to $3.00 and gave the company a “hold” rating in a research note on Wednesday, March 25th. Weiss Ratings restated a “sell (e+)” rating on shares of Cibus in a research note on Wednesday, January 21st. One investment analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $9.00.

Cibus Trading Down 3.1%

Shares of Cibus stock opened at $1.41 on Friday. The stock has a fifty day simple moving average of $2.12 and a 200 day simple moving average of $1.97. Cibus has a 12-month low of $1.09 and a 12-month high of $4.19. The company has a market capitalization of $107.65 million, a P/E ratio of -0.47 and a beta of 1.66. The company has a current ratio of 0.72, a quick ratio of 0.72 and a debt-to-equity ratio of 1.37.

Cibus (NASDAQ:CBUS) last announced its quarterly earnings results on Thursday, May 14th. The company reported ($0.33) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.27) by ($0.06). Cibus had a negative return on equity of 174.58% and a negative net margin of 3,492.30%.The company had revenue of $1.68 million for the quarter, compared to the consensus estimate of $1.61 million.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Goldman Sachs Group Inc. grew its stake in Cibus by 60.4% in the 4th quarter. Goldman Sachs Group Inc. now owns 52,364 shares of the company’s stock valued at $91,000 after purchasing an additional 19,717 shares during the period. Raymond James Financial Inc. grew its stake in Cibus by 31.0% in the 2nd quarter. Raymond James Financial Inc. now owns 53,713 shares of the company’s stock valued at $74,000 after purchasing an additional 12,722 shares during the period. AQR Capital Management LLC bought a new position in shares of Cibus during the 1st quarter worth $73,000. Squarepoint Ops LLC bought a new position in shares of Cibus during the 3rd quarter worth $62,000. Finally, Qube Research & Technologies Ltd bought a new position in shares of Cibus during the 2nd quarter worth $39,000. Institutional investors own 33.81% of the company’s stock.

Cibus News Roundup

Here are the key news stories impacting Cibus this week:

• Positive Sentiment: Cibus beat revenue expectations in Q1, reporting $1.68 million versus the $1.61 million consensus, and its loss per share was slightly better than the Zacks estimate. Article: Cibus (CBUS) Reports Q1 Loss, Beats Revenue Estimates
• Neutral Sentiment: Management also provided a business update and said Cibus has runway into late Q1 2027, which may ease near-term financing concerns, though it also pushed the U.S. rice launch to 2029. Article: Cibus outlines runway into late Q1 2027 while shifting U.S. rice launch to 2029
• Negative Sentiment: Cibus reported Q1 EPS of -$0.33, missing the consensus estimate of -$0.27, reinforcing concerns that profitability remains distant. Article: Cibus earnings report
• Negative Sentiment: Sidoti lowered earnings estimates across multiple periods, including FY2026 to -$1.45 from -$1.18 and FY2027 to -$1.14 from -$0.88, signaling a more cautious outlook from analysts. Article: Sidoti estimate revisions for Cibus

Cibus Company Profile

Cibus, Inc is a biotechnology company specializing in precision gene editing for agricultural applications. Leveraging its proprietary Rapid Trait Development System (RTDS), Cibus develops improved crop traits without the introduction of foreign DNA. The company’s platform enables targeted modifications to plant genomes, allowing for enhanced disease resistance, herbicide tolerance and yield optimization in key row crops.

The company’s core business centers on trait development services and licensing partnerships.